XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments and Fair Value Measurements (Tables)
 9 Months Ended
Sep. 29, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

September 29,
2023 (Successor)
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$40.7 $27.1 $13.6 $— 
Equity securities
16.3 16.3 — — 
Interest rate cap25.1 — 25.1 — 
$82.1 $43.4 $38.7 $— 
Liabilities:
Deferred compensation liabilities$18.9 $— $18.9 $— 
Contingent consideration liabilities— — — — 

$18.9 $— $18.9 $— 
December 30,
2022 (Successor)
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$36.6 $24.8 $11.8 $— 
Equity securities25.5 25.5 — — 
$62.1 $50.3 $11.8 $— 
Liabilities:
Deferred compensation liabilities$26.0 $— $26.0 $— 
Contingent consideration liabilities7.3 — — 7.3 
$33.3 $— $26.0 $7.3 
Schedule of Carrying Amount and Fair Value of Long-term Debt
The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
Successor
September 29, 2023December 30, 2022
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
Debtor-in-Possession Financing due November 2023$280.0 $285.6 $— $— 
Receivables financing facility due December 2023100.0 100.0 — — 
10.00% first lien senior secured notes due April 2025495.0 393.0 475.9 425.9 
10.00% second lien senior secured notes due April 2025321.9 24.2 242.2 216.8 
11.50% first lien senior secured notes due December 2028650.0 574.1 650.0 552.6 
10.00% second lien senior secured notes due June 2029328.3 28.7 175.5 176.7 
Level 2:
2017 Replacement Term loan due September 20271,356.7 1,025.2 1,222.1 1,037.8 
2018 Replacement Term loan due September 2027360.1 272.2 326.9 274.8 
Total Debt$3,892.0 $2,703.0 $3,092.6 $2,684.6 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
Successor
Three Months
Ended
September 29, 2023		Three Months
Ended
September 30, 2022
FFF Enterprises, Inc.24.0 %26.1 %
AmerisourceBergen Corporation
13.3 *
SuccessorPredecessor
Nine Months
Ended
September 29, 2023		Period from
June 17, 2022
through
September 30, 2022		Period from
January 1, 2022
 through
June 16, 2022
FFF Enterprises, Inc.22.4 %25.7 %11.8 %
CuraScript, Inc.**15.6 
* Net sales to this distributor was less than 10.0% of the Company's total net sales for the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
Successor
September 29,
2023		December 30,
2022
AmerisourceBergen Corporation
31.3 %23.3 %
McKesson Corporation
17.8 17.3 
FFF Enterprises, Inc.*16.2 
*Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.
The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:
Successor
Three Months
Ended
September 29, 2023		Three Months
Ended
September 30, 2022
Acthar Gel24.6 %27.0 %
INOmax14.7 17.3 
Therakos13.3 12.5 
APAP11.6 12.4 
SuccessorPredecessor
Nine Months
Ended
September 29, 2023		Period from
June 17, 2022
through
September 30, 2022		Period from
January 1, 2022
 through
June 16, 2022
Acthar Gel23.0 %27.8 %25.4 %
INOmax16.6 17.1 19.0 
Therakos13.4 12.4 12.5 
APAP11.7 12.6 11.0